Effects of Quercetin on Cardiometabolic Outcomes

Last updated: March 3, 2025
Sponsor: University of Central Lancashire
Overall Status: Active - Recruiting

Phase

N/A

Condition

High Cholesterol (Hyperlipidemia)

Metabolic Disorders

Metabolic Syndrome

Treatment

Placebo

Quercetin

Clinical Study ID

NCT06230861
Quercetin cardiometabolic
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy

  • Between 18 & 65 years

  • Non-smoker

  • BMI < 30

  • Able to give informed consent

Exclusion

Exclusion Criteria:

  • Pregnancy

  • Diabetes or any other metabolic/ uncontrolled hypertensive conditions

  • Food allergies to quercetin

  • Habitual consumption of quercetin

  • Not regularly taking medication or antioxidant supplements

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
June 01, 2025

Connect with a study center

  • University of Central Lancashire

    Preston, Lancashire PR4 0PE
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.